A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants

Vaccine

Volumn 30, Issue 38, 2012, Pages 5591-5594

  Odutola, A A ^a   Owolabi, O A ^a   Owiafe, P K ^a   McShane, H ^b   Ota, M O C ^a  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

ESAT6 CFP10; MVA85A; PPD T; TB vaccine, Durability of immunity; Tuberculin skin test

Indexed keywords

ALANINE AMINOTRANSFERASE; BCG VACCINE; CREATININE; CULTURE FILTRATE PROTEIN 10; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; HEMOGLOBIN; MODIFIED VACCINIA VIRUS ANKARA EXPRESSING ANTIGEN 85A VACCINE; UNCLASSIFIED DRUG; UREA;

AFRICA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTHROPOMETRY; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GAMBIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; INFANT; LEUKOCYTE COUNT; MALE; MYCOBACTERIUM TUBERCULOSIS; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REACTION ANALYSIS; RECIPIENT; SIDE EFFECT; THROMBOCYTE COUNT; TUBERCULIN TEST; TUBERCULOSIS; UREA BLOOD LEVEL; VACCINATION;

ACYLTRANSFERASES; AFRICA; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; INFANT; MALE; TIME FACTORS; TUBERCULIN TEST; TUBERCULOSIS VACCINES; VACCINATION; VIRAL VACCINES;

EID: 84864758568     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.054     Document Type: Article

References (15)

1. Report WHO. Global Tuberculosis Control Surveillance, Planning, Financing; 2003.
2. Aaby P., Shaheen S.O., Heyes C.B., Goudiaby A., Hall A.J., Shiell A.W., et al. Early BCG vaccination and reduction in atopy in Guinea-Bissau. Clin Exp Allergy 2000, 30:644-650.
3. Garly M.L., Martins C.L., Bale C., Balde M.A., Hedegaard K.L., Gustafson P., et al. BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. A non-specific beneficial effect of BCG?. Vaccine 2003, 21:2782-2790.
4. McShane H., Pathan A.A., Sander C.R., Keating S.M., Gilbert S.C., Huygen K., et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004, 10:1240-1244.
5. Hawkridge T., Scriba T.J., Gelderbloem S., Smit E., Tameris M., Moyo S., et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis 2008, 198:544-552.
6. Ota M.O., Odutola A.A., Owiafe P.K., Donkor S., Owolabi O.A., Brittain N.J., et al. Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants. Sci Transl Med 2011, 3:88ra56.
7. Scriba T.J., Tameris M., Mansoor N., Smit E., van der Merwe L., Isaacs F., et al. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol 2010, 40:279-290.
8. Sander C.R., Pathan A.A., Beveridge N.E., Poulton I., Minassian A., Alder N., et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. Am J Resp Crit Care 2009, 179:724-733.
9. Goonetilleke N.P., McShane H., Hannan C.M., Anderson R.J., Brookes R.H., Hill A.V. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 2003, 171:1602-1609.
10. Williams A., Goonetilleke N.P., McShane H., Clark S.O., Hatch G., Gilbert S.C., et al. Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs. Infect Immun 2005, 73:3814-3816.
11. Verreck F.A., Vervenne R.A., Kondova I., van Kralingen K.W., Remarque E.J., Braskamp G., et al. MVA85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS One 2009, 4:e5264.
12. Vordermeier H.M., Villarreal-Ramos B., Cockle P.J., McAulay M., Rhodes S.G., Thacker T., et al. Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect Immun 2009, 77:3364-3373.
13. Brookes R.H., Hill P.C., Owiafe P.K., Ibanga H.B., Jeffries D.J., Donkor S.A., et al. Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa. PLoS One 2008, 3:e2921.
14. Moyo S., Isaacs F., Gelderbloem S., Veryer S., Hawkridge Aj, Hatherill M., et al. Tuberculin skin test and QunatiFRERON assay in young children investigated for tuberculosis in South Africa. Int J Tuberc Lung Dis. 2011, 15:1176-1181.
15. Sissolak D., Marais F., Mehtar S. TB infection prevention and control experiences of South African nurses-a phenomenological study. BMC Public Health. 2011, 11:262.